Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: The LEOPARD Study
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 340
- 试验地点
- 30
- 主要终点
- Event-free survival rate
研究概览
简要总结
This is a prospective multicenter biomarker study evaluating the prognostic impact of ctDNA detection at diagnosis in patients with Ewing sarcoma or osteosarcoma.
详细描述
The purpose of this study is to evaluate whether ctDNA in the blood can provide information about the chances of Ewing sarcoma or osteosarcoma coming back after treatment. This research study is evaluating a new advanced laboratory test to detect small pieces of tumor genes in the peripheral blood known as circulating tumor DNA (ctDNA).
Part A : During this part of the research study (Part A) participants will be asked to provide blood samples at pre-defined times. These blood samples may help find specific genetic alterations commonly seen in Ewing sarcoma or osteosarcoma that may allow investigators to learn more about the uses of ctDNA. The results of the ctDNA analysis will not be returned to participants.
Approximately 90 patients will take part in this study across multiple centers.
Part B: This research study is evaluating new advanced laboratory tests to detect small pieces of tumor genes in the peripheral blood known as circulating tumor DNA (ctDNA). Part B of the research study, which focuses on ctDNA tests that can be returned to providers and patients with Ewing sarcoma. This part of the study will allow comparison of commercial ctDNA testing from Foundation Medicine to our research testing. It is expected that about 60 people with Ewing sarcoma will take part in Part B of this research study.
The sponsor of this protocol is Dana-Farber Cancer Institute and is providing funding for the study. Additional funding for this study is provided by the Conquer Cancer Foundation of the American Society of Clinical Oncology, Alex's Lemonade Stand Foundation, Boston Children's Hospital Office of Faculty Development, the Friends of Dana-Farber Cancer Institute, The Harvard Catalyst Program, and the Spada Pediatric Sarcoma Foundation
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 12 Months 至 50 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •For Part A, subjects must meet all of the following eligibility criteria.
- •Age: ≥ 12 months of age at time of study enrollment to 50 years of age
- •Diagnosis: Patients with histologic diagnosis (by institutional pathologist) of newly diagnosed, localized or regionally disseminated Ewing sarcoma or peripheral primitive neuroectodermal tumor (PNET) of bone or soft tissue or; Patients with histologic diagnosis (by institutional pathologist) of newly diagnosed, non-pelvic, localized or regionally disseminated high-grade osteosarcoma. NOTE: Staging will be assessed according to standard of care at the treating center.
- •Prior Therapy:
- •Patients should have only previously had a biopsy, and not had prior attempt at tumor resection.
- •Not yet started chemotherapy or radiation therapy OR patient has started chemotherapy or radiation therapy, but an appropriate pre-treatment baseline sample was collected and processed for ctDNA under a local banking study in DFCI Pediatrics and is available to use for this study.
- •Planned to receive chemotherapy as follows:
- •-- VDC/IE as per COG protocols AEWS0031, AEWS1031 or AEWS1221 (for patients with Ewing sarcoma or PNET); or MAP as per COG protocol AOST0331 (for patients with osteosarcoma).
- •For Part B subjects must meet all of the following eligibility criteria.
- •Age: ≥ 12 months of age at time of study enrollment
- •Diagnosis: Patients with histologic diagnosis (by institutional pathologist) of newly diagnosed Ewing sarcoma or peripheral primitive neuroectodermal tumor (PNET) of bone or soft tissue
- •Prior Therapy:
- •Patients should have had only frontline therapy as per institutional standard, and maintenance therapy if given (no relapse therapy).
- •If frontline systemic therapy already completed (not including maintenance or metastatic site radiation), therapy completed within 6 months of enrollment to Part B.
- •Subjects must have a willing physician provider supporting their participation in Part B.
- •For Part B, providers are eligible to receive the provider survey if they are listed as the primary provider for the patient at the study site.
排除标准
- •For Part A, subjects must not meet any of the following exclusion criteria.
- •Patients with distant metastatic disease.
- •Patients with known Ewing-like sarcoma (e.g., BCOR-CCNB3 or CIC-DUX4 translocated small round cell sarcomas) are not eligible.
- •Patients who are enrolled with an initial diagnosis of Ewing sarcoma and subsequently found to have Ewing-like sarcoma will be replaced. Samples obtained prior to removal from study will be analyzed and reported descriptively. Patients with Ewing-like tumors may continue to provide samples and clinical data until they meet off-study criteria per protocol.
- •Patients weighing < 5 kg at time of diagnosis
- •Patients with a second malignant neoplasm
- •Patients without detectable tumor at the time of study enrollment (ie, complete tumor resection prior to study enrollment)
- •Patients already receiving tumor-directed therapy at the time of study enrollment except when a pre-treatment baseline sample has already been obtained under a local banking study in DFCI Pediatrics that would be eligible for analysis under this study.
- •Patients with osteosarcoma with a pelvic primary tumor site Pregnancy
- •For Part B, subjects must not meet any of the following exclusion criteria.
- •Patients with known Ewing-like sarcoma (e.g., BCOR-CCNB3 or CIC-DUX4 translocated small round cell sarcomas) are not eligible.
- •Samples obtained prior to removal from study will be analyzed and reported descriptively. Patients with Ewing-like tumors may continue to provide samples and clinical data until they meet off-study criteria per protocol
- •Patients weighing < 5 kg at time of enrollment
- •Patients diagnosed with relapsed disease and/or having started therapy directed at disease relapse
- •Pregnancy
- •Resides outside of the United States
- •For Part B, providers at non-study centers will not be eligible to receive the provider survey.
研究组 & 干预措施
REG EWING or OSTEO: ctDNA EVALUATION
This study involves collection of blood samples at pre-specified time points as well as collection of information about this disease.
For each timepoint, submit two tubes of blood (17 mL total or a little more than 3 teaspoons) per standard ctDNA workflow
EWING ctDNA RETURN OF RESULTS
This study involves collection of blood samples at pre-specified time points as well as collection of information about this disease.
For each timepoint, submit two tubes of blood (17 mL total or a little more than 3 teaspoons) to a commercial testing laboratory called Foundation Medicine and one tube of blood (10 mL or 2 teaspoons) to standard ctDNA workflow
干预措施: FoundationOne Liquid CDx (Other)
结局指标
主要结局
Event-free survival rate
时间窗: 2 years
Proportion of patient without an event by baseline detection of ctDNA
次要结局
- Event-free survival rate(2 years)
研究者
David S Shulman, MD
Principal Investigator
Dana-Farber Cancer Institute